PT  - JOURNAL ARTICLE
AU  - Louise Emmett
AU  - Megan Crumbaker
AU  - Andrew Nguyen
AU  - Bao Ho
AU  - Charlotte Yin
AU  - Noah Isheish
AU  - Arun Azad
AU  - John Violet
AU  - Shikha Sharma
AU  - Anthony Joshua
TI  - <strong>Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination <sup>177</sup>Lu PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial).</strong>
DP  - 2019 May 01
TA  - Journal of Nuclear Medicine
PG  - 465--465
VI  - 60
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/60/supplement_1/465.short
4100  - http://jnm.snmjournals.org/content/60/supplement_1/465.full
SO  - J Nucl Med2019 May 01; 60
AB  - 465Background: Despite treatment advances, metastatic castrate resistant prostate cancer (mCRPC) remains a lethal disease. Trials in 177LuPSMA - 617 have demonstrated good efficacy and safety, but not all men respond to treatment, and treatment responses may be limited in duration. Idronoxil is an inhibitor of external NADH oxidase type 2 and has a variety of downstream pro-apoptotic actions including radio-sensitization. We present preliminary results of a phase 1/2 dose escalation trial of LuPSMA and NOX66 in men with heavily pre-treated mCRPC. Methods: 16 men with mCRPC progressing despite docetaxel, cabazitaxel and either abiraterone or enzalutamide were enrolled. Imaging criteria included a PSMA PET/CT intensity SUV max >10 at all sites of measurable disease with no discordant disease on FDG PET/CT. Men required Hb >10ng/mL, Platelets >90 and GFR >40 mls/min. All men received up to 6 doses of 177 Lu-PSMA 617 at 6-weekly intervals; the first 8 men received 400mg idronoxil (suppository) daily cycle days 1-10. Following safety data review, the dose for patients 9-16 was escalated to 800mg idronoxil daily. All men received Dexamethasone 8mg on Day 1 and 4mg days 2,3. Results: To date, all 16 men have received ≥2 doses and 4/16 (25%) 6 cycles. The treatment has been well tolerated. Adverse events (AEs) and PSA responses are summarized in the table below; 1/16 reported an SAE due to pneumonitis and continued on trial without NOX66. 3/16 (19%) have exited trial prematurely due to progressive disease.View this table: Conclusions: Combination LuPSMA-617 + NOX66 demonstrate encouraging early results. Based on these findings, particularly safety, recruitment for a phase II expansion cohort is underway.